NORTH CHICAGO - AbbVie today announced the results of the Phase 2 SLEek study evaluating upadacitinib alone and in combination [ABBV-599 high dose ] in adults with moderately to severely active. | June 1, 2023
- At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary.
A recent study found that Fatigue and disease activity are independent factors as found using the Physician Global Assessment (PGA). The study was published in the journal RMD Open Rheumatic &.
Find out how disease activity, flare rate, and severity differ between pregnant and non-pregnant in (SLE) Systemic Lupus Erythematosus patients. Check out here!